No Data
No Data
Xidian Pharmaceuticals (301130.SZ) has accumulated the repurchase of nearly 5% of its shares, with a total cost of 93.4189 million yuan.
Xidian Pharmaceutical (301130.SZ) announced that as of August 30, 2024, the company has accumulated a total of centralized bidding transactions...
West Point Pharmaceuticals: Semi-Annual Report 2024
West Point Pharmaceuticals: 2024 Semi-Annual Report Summary
Express News | Xipoint Pharmaceutical: The net income in the first half of the year decreased by 19.36% year-on-year.
West Point Pharmaceuticals (301130.SZ): The net income for the first half of the year was 24.4517 million yuan, a year-on-year decrease of 19.36%.
Geelonghui, August 28th - Xiduo Pharmaceuticals (301130.SZ) announced its semi-annual report for 2024, with operating income of 0.129 billion yuan, a year-on-year increase of 13.04%; net income attributable to shareholders of the listed company was 24.4517 million yuan, a year-on-year decrease of 19.36%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.8314 million yuan, a year-on-year increase of 39.10%; basic earnings per share was 0.3026 yuan.
Xide Pharmaceutical (301130.SZ): Approved products and products under registration that are being researched do not include monkeypox treatment drugs such as Tekovir.
On August 21, Gralon Pharmaceuticals (301130.SZ) stated on the investor interaction platform that the company's approved products and research products in the registration process do not include monkeypox treatment drugs such as Tocilizumab.
No Data